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Background:
 
 Criticism has been made of observational
studies in clinical practice because of their failure to
control for unobserved factors that correlate with both
initial treatment selection and observed outcomes.
 
Method:
 
 A two-stage statistical model was applied to
data obtained from a large general practitioner medical
records database (DIN-LINK) to estimate the effect of
initial antidepressant selection on the duration of anti-
depressant therapy and on the likelihood of being pre-
scribed an average daily dose above the minimum rec-
ommended dose. The statistical model controlled for
unobserved factors correlated with initial treatment se-
lection and the observed outcomes as well as for ob-
served confounders.
 
Results:
 
 Unobserved factors correlated with treatment
selection were not a statistically significant determinant
of the number of days of antidepressant therapy. How-
ever, unobserved factors correlated with treatment se-
lection were a statistically significant determinant of the
likelihood of receiving an average dose during therapy
greater than the minimum recommended. After control-
ling for relevant confounders, those patients who began
treatment with sertraline as opposed to fluoxetine had
fewer days of antidepressant therapy and were more
likely to receive average doses greater than the mini-
mum recommended during therapy.
 
Conclusion:
 
 Unobserved factors correlated with treat-
ment selection can impact outcomes in observational
studies and should be tested and controlled for when-
ever possible.
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Introduction
 
To ensure a high degree of internal validity, con-
trolled clinical trials of pharmaceuticals hold indi-
viduals’ behavioral and health system effects con-
stant. Yet variability in the behavior of patients
and prescribers can ultimately lead to variability
in outcomes between treatments in clinical prac-
tice. As a result, prospective naturalistic trials and
retrospective database studies conducted in clini-
cal practice settings are frequently used in phar-
macological assessments to complement findings
from randomized clinical trials. An important
contribution of retrospective database studies is
that they can identify associations between treat-
ment selection and outcomes in the context of pa-
tient and prescriber behavior.
In controlled trials, initial random assignment
theoretically mitigates potential biases due to the
influence of both observed and unobserved factors
because the randomization process is ignorant of
the particular characteristics of the patients being
assigned. Criticism has been directed at retrospec-
tive studies that use data collected in nonrandom-
ized environments for their failure to control for
not only observed factors, but also unobserved
factors that may be correlated with both the initial
treatment selection and observed outcomes [1,2].
If this type of unobserved confounder influences
the outcome, but is ignored in the analysis, then
estimates of the effects of alternative drug treat-
ments on the outcome will be statistically biased.
Nonrandom selection of patients for alternative
drug treatments will result in erroneous inferences
concerning the relative effectiveness of alternative
treatments.
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Statistical methods can be applied to retrospec-
tive data to control for unobserved factors corre-
lated with initial treatment selection, as well as for
observed factors that influence the subsequent
outcomes. The purpose of this study is to illustrate
how sample selection modeling may be used in ret-
rospective database studies examining the impact of
alternative treatments on health care outcomes, spe-
cifically in cases where the outcome variable of in-
terest may not necessarily be normally distributed.
Heckman [3] proposed a two-step approach for
testing and correcting sample selection bias. Re-
cent empirical studies of retrospective data in
pharmacoeconomics have used this method to as-
sess health care outcomes associated with alterna-
tive antidepressant treatments [4–6]. The first step
involves estimation of a treatment selection model.
The study sample is segmented in this step into
mutually exclusive categories for the dependent
variable (e.g., those that are and are not treated).
The estimated probabilities of treatment from this
regression are used to calculate the risk of not re-
ceiving a particular treatment, given that treat-
ment was an option. In the second step, an out-
come equation is estimated by ordinary least
squares and this risk variable entered as an addi-
tional explanatory variable. Standard errors of pa-
rameter estimates of the outcome equation must
account for additional variability introduced by
the estimated selection term.
The risk variable (also known as the selection
term) controls for the effect of unobserved vari-
ables correlated with treatment selection on the
outcome variable. The statistical significance of
selection bias is assessed by the 
 
t
 
-statistic associ-
ated with the parameter estimate of the outcome
equation selection term. Specifically, a significant
finding rejects the null hypothesis that unobserved
factors correlated with treatment choice do not af-
fect the outcome under study. If the selection term
is significant then unbiased parameter estimates
are obtained from the selection-corrected regres-
sion. If, however, the selection term is insignifi-
cant, unbiased results are obtained from a regres-
sion that excludes the selection term from the set
of explanatory variables.
Heckman’s two-step method implementation
is relatively easy. For research applications con-
cerning health care, however, the model is some-
what limited. Consistent parameter estimates are
ensured only if the outcome variable is normally
distributed. As such, outcome variables that are
discrete counts (e.g., the number of therapy days)
or indicators (e.g., whether or not an average dose
is greater than the recommended dose) cannot be
handled with this procedure. Count data is typi-
cally bounded by zero and often naturally skewed.
Applying linear regression to an indicator variable
may result in predicted probabilities that lie out-
side the unit interval as well as estimated variances
that are negative.
Sample selection correction methods that apply
less parametric structure to the problem have been
developed in response. The least restrictive of
these include the semiparametric and series-expan-
sion (semi-nonparametric) methods of Lee [7] and
Ichimura and Lee [8]; however, such methods can be
quite difficult to estimate. The generalized method of
moments estimator of Mullahy [9] is another al-
ternative, although in some cases it is less efficient
in a statistical sense than those that impose some
structure [10].
The methodology applied below accounts for
the joint determination of treatment choice and
levels of the outcome measures of interest. In addi-
tion, it tests and corrects for the influence of sys-
tematic sample selection on these levels. The sam-
ple selection algorithm used [11] is appropriate for
many types of outcome measures. The method
yields consistent parameter estimates not only for
those measures that are continuous and normally
distributed, but also for those that represent dis-
crete integers (e.g., number of days of therapy)
with distributions that may contain a large fre-
quency of zero valued observations (e.g., the num-
ber of hospitalizations). It is also appropriate for
variables that are binary (e.g., whether or not the
dose prescribed is above the minimum recom-
mended dose).
In this paper, this method is illustrated using
data from the United Kingdom on prescribing pat-
terns for primary care patients to ascertain whether
the duration of antidepressant therapy and dosing
differed among those who initiated therapy on flu-
oxetine as opposed to sertraline. Fluoxetine and
sertraline are among the most common selective se-
rotonin reuptake inhibitors (SSRIs) prescribed in
clinical practice. Their use in this setting has been
extensively studied [12–18]. These analyses have
found differences between the two drugs in terms
of prescribing patterns, as measured by the dura-
tion of therapy and dosing. However, none of these
studies controlled for the possibility that differences
may have resulted merely from the influence of
nonrandom treatment selection. As such, results
from these previous studies may be biased [19,20].
Application of the sample selection methodology
described below allows testing of whether sample
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selection bias exists and results in estimates appro-
priately adjusted for the presence of such bias.
 
Methods
 
Statistical Model
 
A two-stage statistical model developed by Terza
[11] was used to estimate the number of therapy
days and probability that the average prescribed
daily dose during treatment was greater than the
minimum recommended daily dose. This two-
stage method of moments estimator is statistically
consistent and asymptotically normal for a broad
class of nonlinear second stage regressions. Sec-
ond-stage regressions estimated by ordinary least
squares for continuous variables, probit or logit
for binary variables, or nonlinear least squares ex-
ponential regression for count variables, are in-
cluded within this class.
As with the Heckman procedure, the first stage
of the model involves estimating the probability that
a patient receives sertraline as opposed to fluoxetine
by a maximum likelihood procedure (probit or
logit). For this study, the treatment choice of sertra-
line versus fluoxetine was modeled as a function of
patient characteristics (e.g., age, gender, and indica-
tors of disease severity) and two variables that
proxy for general practice antidepressant prescrib-
ing patterns. Previous studies showed that variables
such as these appear to be important determinants
of initial antidepressant selection [6,17,21].
Physician prescribing patterns may be shaped
by a number of influences, including previous ex-
perience and information received about the prod-
uct and its use. Simon and Fishman [21] found
that habitual prescribing preferences were a stron-
ger determinant of initial antidepressant drug se-
lection than patient characteristics. Evidence also
suggests that general practitioners (GPs) may pre-
scribe the same antidepressant for all patients
rather than consider individual patient character-
istics when selecting a treatment [22]. Similar to
the Simon and Fishman approach, the two vari-
ables used in this study to capture these effects
were defined as the percentage of the general prac-
tice study antidepressant prescriptions that were
fluoxetine and sertraline on the date of the pa-
tient’s initiation of therapy.
As with Heckman’s procedure, the two-stage
methods of moments estimation involves calcula-
tion of a sample selection correction term. This
term will control for biases that arise from the se-
lection of patients into alternative antidepressant
categories based on unobservables that are uncor-
related with other (exogenous) explanatory vari-
ables in the model. One component of the term is
a parameter that captures the correlation between
unobserved factors (e.g., patient and/or prescriber
characteristics) that influence initial treatment se-
lection and the outcome of interest (either therapy
days or the likelihood of being prescribed an aver-
age daily dose above the minimum recommended
dose). The estimate of this parameter, referred to
as theta in Terza’s paper, will reflect the existence
(or nonexistence) of selection bias. In particular, a
significant estimate rejects the null hypothesis that
unobserved factors correlated with treatment choice
do not affect the outcome under study.
Two-stage method of moments regression mod-
els were estimated to test the null hypothesis of no
difference between fluoxetine and sertraline pa-
tients in the duration of initial antidepressant ther-
apy and the likelihood of receiving an average
daily dose above the minimum recommended. The
duration of therapy dependent variable was con-
structed as a count of the number of antidepres-
sant prescription days during the 180 days follow-
ing the initiation of treatment. An exponential
specification was used, and the regression was es-
timated by nonlinear least squares. The exponen-
tial specification is appropriate for non-negative,
integer-valued measures [23]. The dosing binary
dependent variable was set equal to one if the pa-
tient’s average daily dose during treatment was
greater than the minimum recommended dose and
set equal to zero otherwise. A probit specification
was used to judge the parameter estimates associ-
ated with the explanatory factors of the dichoto-
mous variable regression model.
Minimum recommended daily doses used were
those quoted in the British National Formulary
[24], 20 mg for fluoxetine and 50 mg for sertraline.
The minimum recommended dose can optimize the
risk:benefit ratio of a drug, and is often based on ev-
idence from controlled clinical trials. Replication in
clinical practice of efficacy rates, side-effect profiles,
and drop-out rates obtained in such stylized settings
is unlikely. As such, actual doses used in clinical
practice may be guided by physician experience
with patient outcomes and tolerability. There are
economic consequences of dosing decisions in clini-
cal practice. List prices in the United Kingdom for
1997 (Monthly Index of Medical Specialties, 1998)
indicated that the monthly cost of fluoxetine (20
mg) was £20.77 while the monthly cost of sertraline
(50 mg) was £26.51. Differences in prescribed daily
doses could alter this price differential.
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The main explanatory variable in the second-
stage equations was a binary indicator of drug
choice set equal to one for sertraline and set equal
to zero for fluoxetine (the more frequently pre-
scribed antidepressant). Variables were also in-
cluded to control for baseline differences in pa-
tient demographics (age and gender) and location
in the country. Other variables were included to
control for patient baseline comorbid conditions
at the index date or in the prior period: four bi-
nary indicators for depression diagnosis at the in-
dex date, i.e., endogenous depression, reactive de-
pression, depressed, and on examination depressed,
with depression not otherwise specified as the ref-
erence group; binary indicators for coronary ar-
tery disease and diabetes in the 180-day period
prior to initiation of therapy (diseases that are of-
ten comorbid with depression); counts of the num-
ber of anxiolytic, sedative-hypnotic, antipsychotic,
and other medicine prescriptions in the 180-day
prior period; GP visits; GP, psychotherapy, and
lab referrals in the 180-day prior period; psychiat-
ric accident and emergency (A & E), general A &
E, general non-A & E admissions in the 180-day
prior period; and a count of the number of unique
Psychiatric Diagnostic Groups (PDGs) [25] that a
patient had in the 180-day prior period. PDGs are
a method of classifying major psychiatric condi-
tions and serve in the regression context as proxies
for general mental health. Note that although the
model is theoretically identified on the basis of
nonlinearities, the exclusion of the proxies for gen-
eral practice prescribing preferences from the sec-
ond stage regressions assists in identification.
As described above, the parameter theta was es-
timated to test and control for the potential self-
selection into the two different antidepressants. If
theta is statistically significant, then selection bias
is an important factor to consider in the outcome
equations. By including both the observed factors
and adjusting for unobserved factors correlated
with initial treatment selection, the estimated ef-
fect of the antidepressant will be free of selection
bias that is attributable to unobserved factors un-
correlated with the exogenous explanatory vari-
ables in the model. If the selection parameter is in-
significant then the null hypothesis of no sample
selection cannot be rejected. In this case, unbiased
parameter estimates can be obtained from regres-
sions that do not estimate theta.
The incremental or marginal impact of initiating
therapy on sertraline as opposed to fluoxetine on
either outcome was calculated as the difference be-
tween the predicted outcome evaluated with the
sertraline indicator variable set equal to one and the
predicted outcome with the sertraline indicator set
equal to zero. Other explanatory variables were set
equal to the overall sample mean values (or modal
values for qualitative variables) in these calcula-
tions. Standard errors associated with the marginal
effects were calculated using the delta method [26].
Software to estimate the statistical model was pro-
vided by Joseph Terza Econometric Consulting,
Inc. (State College, Pennsylvania USA).
 
Data
 
The analysis file used in this study was constructed
from the 1992–1997 panels of the Doctors’ Inde-
pendent Network (DIN-LINK), maintained by
CompuFile Ltd. (Woking, UK). These files contain
standardized medical and prescription records for
approximately 750,000 patients from 100 general
practices in the United Kingdom.
To ensure that the antidepressant prescribing be-
haviors studied were not part of an earlier episode
of treatment, each patient had to have a 6-month
antidepressant-free prior period. An episode of an-
tidepressant therapy was then constructed using an
intent-to-treat design, since the hypotheses of the
study concerned the impact of initial drug selection
on subsequent outcomes. Under this design, pa-
tients’ subsequent experiences in the study period
are attributed to the original drug selected [27].
An index date was defined as the date on which
the first prescription for the study antidepressant
(fluoxetine or sertraline) was prescribed, accom-
panied by a depression-related diagnosis within a
30-day period. Five depression-related diagnoses
were collected, including endogenous depression,
reactive depression, depressed, on examination de-
pressed, or depression not otherwise specified.
These diagnoses are consistent with those used
and validated in earlier analyses of the DIN-LINK
data [14,15]. The period examined for each pa-
tient was 6 months. The end of the patient’s treat-
ment coincided with the duration of the last pre-
scription for any antidepressant.
Patients were excluded from the final sample if
they:
• did not have a 180-day prestudy period;
• did not have a minimum of 180 days of con-
tinuous health care coverage in the same GP
practice after the index date;
• were prescribed more than one index study an-
tidepressant at the index date;
• had used antidepressants in the 180-day prior
period;
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• had multiple records of the study antidepres-
sant on the index date;
• were younger than 18 on the index date.
The final analytical file included 4555 patients
in 99 practice groups that were prescribed either
fluoxetine (
 
N
 
 
 

 
 3817) or sertraline (
 
N
 
 
 

 
 738) for
the treatment of depression.
The SAS package (SAS Institute, Cary, NC USA)
was used to construct the final analytical file.
 
Results
 
In the sample, 83.8% (
 
N
 
 
 

 
 3817) of patients initi-
ated therapy with fluoxetine as compared to
16.2% (
 
N
 
 
 

 
 738) with sertraline (Table 1). The
average number of days of antidepressant therapy
for those who initiated therapy on fluoxetine was
90.9 with standard deviation of 57.2, while for
those who initiated on sertraline, the mean num-
ber was 77.3 with standard deviation of 57.3 (
 
P
 
 
 

 
.0001). Approximately 49% of sertraline patients
and 36% of the fluoxetine patients discontinued
therapy with their original antidepressant and
were not given another prescription for their orig-
inal antidepressant for the remainder of the study
period. The final analytical sample included all
patients, irrespective of actual therapy length.
While most of the patients who initiated therapy
on fluoxetine (95.4%) had an average prescribed
daily dose equal to the minimum recommended
dose of 20 mg, 4.6% of patients had a prescribed
average daily dose above this minimum. A major-
ity of sertraline patients (58.9%) had a prescribed
average daily dose equal to the minimum recom-
mended dose (50 mg); approximately 41% of pa-
tients in this group had a prescribed average daily
dose above the minimum recommended dose.
 
Table 1
 
Descriptive statistics by drug selection
 
Fluoxetine (
 
N
 
 
 

 
 3817) Sertraline (
 
N
 
 
 

 
 738)
 
N
 
Percentage
 
N
 
Percentage
 
P
 
 value
Average drug dose greater than minimum recommended dose
Yes 175 4.6 303 41.1 .001
No 3642 95.4 435 58.9
Index depression diagnosis
Depression not otherwise specified 1847 48.4 339 45.9 .007
Endogenous depression 946 24.8 167 22.6
Reactive depression 519 13.6 109 14.8
Depressed 430 11.3 94 12.7
On examination depressed 75 1.96 29 3.9
Location
Southern England 1959 51.3 332 45.0 .001
Northern England & Scotland 1557 40.8 313 42.4
Wales 301 7.9 93 12.6
Gender
Male 982 25.7 198 26.8 .532
Female 2835 74.3 540 73.2
Indicators of other medical conditions in the 180-day prior period
Coronary artery disease 187 4.9 41 5.6 .454
Diabetes 84 2.2 16 2.2 .956
Days of antidepressant therapy 90.88 57.2 77.31 57.3 .000
Age (years) 44.52 17.3 46.14 18.8 .030
Number of medical occurrences in the 180-day prior period
Anxiolytic prescriptions 0.09 0.7 0.12 0.9 .365
Sedative-hypnotics prescriptions 0.22 1.0 0.28 1.1 .212
Antipsychotic prescriptions 0.07 0.57 0.02 0.3 .001
Other prescriptions 17.26 18.7 16.98 18.0 .705
General Practitioner visits 6.80 6.1 6.76 6.0 .859
General Practitioner referrals 1.01 2.4 1.18 2.7 .106
Psychotherapy referrals 0.08 0.5 0.14 0.7 .028
Lab referrals 0.09 0.8 0.10 0.6 .519
Psychiatric A & E admissions 0.01 0.1 0.02 0.2 .060
General A & E admissions 0.05 0.3 0.06 0.4 .737
General non-A & E admissions 0.13 0.7 0.15 0.8 .518
PDG occurrence in the 180-day prior period
(count of number of unique PDGs) 0.26 0.5 0.26 0.5 .916
General practice drug preference
Frequency of general practice fluoxetine prescriptions 0.22 0.08 0.17 0.07 .000
Frequency of general practice sertraline prescriptions 0.04 0.04 0.08 0.05 .000
 
P
 
 values for indicator variables are based on chi-square tests of independence. All other 
 
P
 
 values are based on 
 
t
 
-tests.
 440
 
Neslusan et al.
 
For the first prescription, 98.4% of patients in
the fluoxetine group were prescribed a daily dose
of 20 mg, with the remainder of prescriptions at
higher doses. For sertraline patients, 63.7% were
prescribed a daily dose of 50 mg at the first pre-
scription. An additional 15.8% of sertraline pa-
tients received 100 mg, 20.2% received 150 mg,
with the remainder at other dose levels. Similar
average daily dose patterns were observed for sub-
sequent prescriptions. Patients who initiated ther-
apy on fluoxetine had an average daily dose pre-
scribed during treatment of 20.8 mg (
 
SD
 
 
 

 
 5.6).
Patients who initiated therapy on sertraline had an
average daily dose prescribed during treatment of
79.0 mg (
 
SD
 
 
 

 
 38.9).
Descriptive statistics for the explanatory vari-
ables noted in the methods section are also de-
picted in Table 1. Patients initiating therapy on
fluoxetine were slightly younger, on average, than
their counterparts that began therapy on sertra-
line. These subsamples also appear to be different
in terms of where they resided and the diagnosis
they received. In terms of medical events in the six
months prior to their depression treatment, fluox-
etine patients had significantly more antipsychotic
prescriptions and fewer psychotherapy referrals,
on average. As expected, fluoxetine patients were
more likely to receive their prescription from a GP
practice that tended to prescribe fluoxetine more
frequently; the same held true for sertraline pa-
tients visiting practices that tended to prescribe
sertraline more frequently.
Results for the first stage antidepressant selec-
tion equation are reported in Table 2. The sign on
the coefficients indicates the directional effect of
the characteristic on the change in probability of
being prescribed sertraline versus fluoxetine. The
two variables capturing the likelihood of the prac-
tices to prescribe the two drugs are highly signifi-
cant and of the expected signs, a finding consistent
with an earlier study [17]. Patients whose general
practice tended to prescribe sertraline (fluoxetine)
 
Table 2
 
Coefficients and 
 
t
 
-statistics from 1st stage model of drug choice
 
Variable Coefficients
 
†
 
t
 
-statistics
Demographics
Age at index date 0.005 3.479*
Female indicator 0.014 0.244
Location
Wales indicator
 

 
0.149
 

 
1.434
Southern England indicator
 

 
0.221
 

 
4.087*
Index depression diagnosis
Endogenous depression 0.003 0.048
Reactive depression 0.155 1.972*
Depressed 0.095 1.196
On examination depressed 0.490 3.353*
Counts of medical occurrences in the 180-day prior period
Anxiolytic prescriptions 0.024 0.722
Sedative-hypnotics prescriptions 0.033 1.376
Antipsychotic prescriptions
 

 
0.192
 

 
2.695*
Other prescriptions
 

 
0.002
 

 
0.532
General Practitioner visits 0.001 0.101
General Practitioner referrals 0.004 0.351
Psychotherapy referrals 0.088 2.098*
Lab referrals
 

 
0.010
 

 
0.289
Psychiatric A & E admissions 0.472 2.809*
General A & E admissions 
 

 
0.048
 

 
0.608
General non-A & E admissions 0.035 1.011
PDG occurrence in the 180-day prior period
Number of unique PDGs
 

 
0.006
 

 
0.113
Indicators of other medical conditions in the 180-day prior period
Coronary artery disease 0.022 0.184
Diabetes
 

 
0.027
 

 
0.156
General Practitioner drug preference
Frequency of General Practitioner sertraline prescriptions 12.117 21.394*
Frequency of General Practitioner fluoxetine prescritptions
 

 
3.818
 

 
11.275*
% correctly predicted
Overall 85.005
Likelihood ratio test statistic (d.f. 
 

 
 24) 813.426
 
*Indicates 
 
P
 
 
 

 
 .01.
 
†
 
The sign on the coefficient indicates the direction of the change in probability of being prescribed sertraline relative to fluoxetine that is associated with the
characteristic.
PDG, Psychiatric Diganostic Groups
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had a higher probability of being prescribed ser-
traline (fluoxetine), all else being equal. Older in-
dividuals, as well as patients in the diagnosis cate-
gories “reactive depression” and “on examination
depressed” were more likely to receive sertraline
as opposed to fluoxetine. Subjects residing in
southern England were less likely to initiate ther-
apy on sertraline. Patients with more antipsy-
chotic prescriptions, fewer psychotherapy refer-
rals, and psychiatric A & E admissions in the 180-
day prior period were also less likely to initiate
treatment for depression on sertraline.
Tables 3 and 4 present the second stage results
for duration and dosing analyses, respectively. Col-
umns 1 and 2 in each table display the results unad-
justed for selection, while columns 3 and 4 display
those from the selection model. In Table 3, the sign
on the coefficients indicates the direction of the ef-
fects of characteristics on the duration of therapy.
In Table 4, the sign on the coefficients indicates the
direction of the change in probability of being pre-
scribed an average daily dose during treatment
higher than the minimum recommended dose.
Patients who began therapy on sertraline were
more likely to have a shorter duration of therapy
after controlling for observable confounders (Ta-
ble 3). This finding rejects a main null hypothesis
of this study, namely that there is no difference be-
tween those initiating therapy on sertraline as op-
posed to fluoxetine in terms of therapy duration.
The significance and sign of this result was gener-
ally robust to alternative specifications of the ex-
planatory variables in the statistical model. The
selection parameter theta was statistically insignif-
icant. This result implies that unobserved factors
correlated with initial treatment selection and du-
ration are not a significant determinant of the du-
ration of therapy for these primary care patients.
Since selection bias did not appear to be an is-
sue for this outcome measure in this sample, the
parameter estimates from the unadjusted model
were used to obtain an estimate of the size of the
 
Table 3
 
Coefficients and 
 
t
 
-statistics from 2nd stage model of days of antidepressant therapy
 
Unadjusted Results Selection Model Results
Variable Coefficients
 
†
 
t
 
-statistics Coefficients
 
†
 
t
 
-statistics
Demographics
Age at index date 0.003 4.466* 0.003 4.428*
Female indicator
 

 
0.018
 

 
0.845
 

 
0.018
 

 
0.848
Location
Wales indicator
 

 
0.098
 

 
2.519*
 

 
0.099
 

 
2.536*
Southern England indicator 0.004 0.174 0.004 0.200
Index depression diagnosis
Endogenous depression 0.033 1.416 0.033 1.426
Reactive depression
 

 
0.081
 

 
2.575*
 

 
0.081
 

 
2.584*
Depressed
 

 
0.084
 

 
2.625*
 

 
0.084
 

 
2.636*
On examination depressed
 

 
0.056
 

 
0.921
 

 
0.058
 

 
0.946
Counts of medical occurrences in the 180-day prior period
Anxiolytic prescriptions
 

 
0.001
 

 
0.037
 

 
0.001
 

 
0.044
Sedative-hypnotics prescriptions
 

 
0.013
 

 
1.278
 

 
0.013
 

 
1.288
Antipsychotic prescriptions 0.021 1.350 0.022 1.377
Other prescriptions 0.000
 

 
0.112 0.000
 

 
0.107
General Practitioner visits 0.003 1.033 0.003 1.041
General Practitioner referrals
 

 
0.001
 

 
0.154
 

 
0.001
 

 
0.173
Psychotherapy referrals 0.023 1.445 0.023 1.411
Lab referrals
 

 
0.015
 

 
0.875
 

 
0.015
 

 
0.881
Psychiatric A & E admissions 0.018 0.258 0.016 0.227
General A & E admissions 0.007 0.285 0.007 0.281
General non-A & E admissions 0.013 1.150 0.013 1.136
PDG occurrence in the 180-day prior period
Number of unique PDGs 0.075 3.854* 0.075 3.850*
Indicators of other medical conditions in the 180-day prior period
Coronary artery disease
 

 
0.020
 

 
0.446
 
0.020 0.446
Diabetes 0.010 0.148 0.010 0.152
Drug choice
Sertraline 0.148 5.115* 0.131 2.054*
Selection parameter
Theta — — 0.011 0.290
Sums of squared residuals 14,605,024 14,604,748
* Indicates P  .01.
†The sign on the coefficient indicates the direction of the change in duration that is associated with the characteristic.
PDG, Psychiatric Diganostic Groups
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incremental effect. For the average subject in the
sample, the parameter estimates from this model
imply an incremental effect of 11.289 days (SE
4.352 days). In other words, initiating therapy on
sertraline as opposed to fluoxetine for the average
patient would be expected to result in 11.289
fewer days of antidepressant therapy.
Other statistically significant variables in this
model included: age, location, reactive depression
and depressed, as well as the prior period PDG
count. Older patients as well as those with a greater
number of unique PDGs during the 6 months prior
to treatment had more days of therapy. Patients re-
siding in Wales as opposed to Northern England or
Scotland and subjects diagnosed with reactive de-
pression or depressed as opposed to “depression
not otherwise specified” had shorter durations.
Patients beginning therapy on sertraline were
also more likely to have an average daily dose dur-
ing treatment greater than the minimum recom-
mended dose after controlling for observable and
unobservable factors correlated with drug selec-
tion (Table 4, column 3). This finding rejects the
other main null hypothesis of this study, namely
that there is no difference between those initiating
therapy on sertraline as opposed to fluoxetine in
terms of receiving an average dose greater than the
recommended minimum dose during treatment.
The selection parameter theta was statistically sig-
nificant. Unobserved factors correlated with initial
treatment selection and dosing appear to have
been a significant determinant whether doses re-
ceived were greater than the minimum recom-
mended. These results were robust to alternative
specifications of the explanatory variables in the
statistical model.
Using the parameter estimates from the model
adjusted for sample selection (Table 4, column 3)
Table 4 Coefficients and t-statistics from 2nd stage model of average dosage greater than the minimum
Unadjusted Results Selection Model Results
Variable Coefficients† t-statistics Coefficients† t-statistics
Demographics
Age at index date 0.003 1.603 0.002 1.016
Female indicator 0.111 1.678 0.132 1.590
Location
Wales indicator 0.512 4.356** 0.308 2.090**
Southern England indicator 0.292 4.805** 0.204 2.581**
Index depression diagnosis
Endogenous depression 0.041 0.566 0.027 0.296
Reactive depression 0.017 0.187 0.004 0.033
Depressed 0.261 2.570** 0.334 2.453**
On examination depressed 0.175 1.060 0.001 0.005
Counts of medical occurrences in the 180-day prior period
Anxiolytic prescriptions 0.011 0.280 0.050 1.016
Sedative-hypnotics prescriptions 0.086 2.559** 0.103 2.275**
Antipsychotic prescriptions 0.124 2.878** 0.121 2.326*
Other prescriptions 0.004 1.273 0.006 1.278
General Practitioner visits 0.012 1.151 0.014 1.000
General Practitioner referrals 0.005 0.445 0.009 0.589
Psychotherapy referrals 0.077 1.858 0.086 1.800
Lab referrals 0.036 1.256 0.049 1.389
Psychiatric A & E admissions 0.427 2.297** 0.473 2.267**
General A & E admissions 0.056 0.670 0.053 0.452
General non-A & E admissions 0.029 0.632 0.054 0.900
PDG occurrence in the 180-day prior period
Number of unique PDGs 0.214 3.621** 0.187 2.514**
Indicators of other medical conditions in the 180-day prior period
Coronary artery disease 0.091 0.655 0.055 0.291
Diabetes 0.126 0.639 0.116 0.447
Drug choice
Sertraline 1.525 24.976** 1.158 8.286**
Selection parameter
Theta — 0.269 2.579**
Sums of squared residuals % correctly predicted
Overall 89.835 333.063
Likelihood ratio test statistic (d.f.  23) 742.647
*Indicates P .05; **indicates P  .01.
†The sign on the coefficient indicates the direction of the change in probability of being prescribed an average dose during treatment higher than the minimum rec-
ommended dose that is associated with the characteristic.
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results in an incremental effect of 22.85% (SE
5.27%) for the average patient in the sample. If
sample selection had not been controlled, the in-
cremental effect would have been substantially
higher at 33.88% (SE 2.23%).
Other results of the dosing model indicated that
patients who resided outside Northern England or
Scotland or who were diagnosed as depressed ver-
sus “depression not otherwise specified” were more
likely to have the minimum recommended average
daily dose during treatment. Patients with fewer
sedative-hypnotic prescriptions, more antipsychotic
prescriptions, more unique PDGs, and more psychi-
atric A & E admissions in the preperiod had an in-
creased likelihood of an average daily dose greater
than the minimum recommended dose.
Discussion
This study showed differences in the treatment du-
ration and likelihood of being prescribed a daily
dose above the minimum recommended dose for
patients who initiated therapy on sertraline and
fluoxetine in primary care in the United Kingdom.
Features of this study included the use of data
from clinical practice and controls for both ob-
served and unobserved factors correlated with
both treatment selection and the outcomes under
study—prescribed daily doses and the duration of
therapy. Although all the SSRIs have equal effi-
cacy, their use in clinical practice can vary due to
differences in tolerability, dosing regimen, ease of
use, and other factors.
A previous study also found differences among
the SSRIs in the duration of initial antidepressant
therapy [28]. Differences in the side-effects profiles,
which may be more pronounced at higher doses, can
contribute to differences in therapy length among
the SSRIs [29]. Longer duration of therapy is often
associated with improved clinical outcomes [30].
The dosing results reported here are consistent
with another study [18] that analyzed data from a
primary care psychiatry setting in Spain. This
study also found that patients who initiated ther-
apy on sertraline as opposed to fluoxetine were
more likely to have an average daily dose above
the minimum recommended dose. In the Spanish
study, patients met DSM-IIIR criteria for major
depressive disorder and had no baseline differ-
ences by initial antidepressant in disease severity
as measured by the Hamilton Depression Rating
and Clinical Global Impression scales. Although
antidepressant doses higher than the minimum
recommended may provide a greater clinical effect
in some patients, higher doses may also increase
the likelihood of side effects and lead to higher an-
tidepressant costs.
The parameter estimate of theta was statistically
significant in the model that considered the likelihood
of having an average dose during therapy greater
than the minimum recommended. This result sug-
gests that unobserved factors such as patient and pre-
scriber characteristics not measured in the data, but
correlated with initial treatment selection and ob-
served doses, are a significant determinant of the like-
lihood of being prescribed an average daily dose
above the minimum recommended. Since the statisti-
cal method controls for unobserved factors correlated
with treatment choice, they cannot explain the signif-
icant effect of initial antidepressant selection on the
dose outcome. In addition, the size of the effect of pa-
tients initiating therapy on sertraline as opposed to
fluoxetine on the likelihood of receiving an average
daily dose above the minimum recommended dose
would have been biased if sample selection methods
were not used. Unobserved factors correlated with
initial drug choice were not found to be a significant
determinant of the duration of therapy, although
treatment type did matter. The statistical methodol-
ogy applied here addresses concerns raised in earlier
literature about the need to control for the potential
effect of unobserved factors when comparing out-
comes on fluoxetine and sertraline [19,20].
It is not possible with these data to identify the
reason for the differential between the two antide-
pressants in the duration of therapy or the likeli-
hood of receiving an average daily dose above the
minimum recommended dose. Nor is it possible to
evaluate patient-associated clinical outcomes with
the observed regimen since clinical symptomatol-
ogy data were unavailable in DIN-LINK. It is con-
ceivable that some patients in the study sample did
not meet the clinical criteria for major depressive
disorder and that some patients who were receiv-
ing their antidepressant for major depressive dis-
orders were excluded. While the diagnoses of af-
fective disorders are not perfect in these data, it is
unlikely that there is systematic bias across the flu-
oxetine and sertraline groups. Similarly, it is un-
likely that a systematic bias due to miscoding of
depression diagnoses exists in these data. While it
was impossible to know whether patients were
taking their medications, it is further unlikely that
any differences in compliance were systematic
across the treatment groups.
Future research might include randomized, pro-
spective analysis comparing these outcomes among
444 Neslusan et al.
the SSRIs as a way to further validate the retrospec-
tive analysis presented here. As occurred with the
development of the Heckman model [31,32], fur-
ther theoretical work extending the Terza model to
allow for polychotomous choices in the treatment
choice equation would be valuable as well. The sta-
tistical methods applied in this study would be use-
ful in other areas of pharmacoeconomics and
health outcomes research such as in the evaluation
of health, utilization, and cost outcomes in clinical
practice settings across alternative therapies.
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